Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages 231-239

  Behringer, Karolin ^a   Mueller, Horst ^a   Goergen, Helen ^a   Thielen, Indra ^a   Eibl, Angelika Diana ^a   Stumpf, Volker ^a   Wessels, Carsten ^a   Wiehlpütz, Martin ^a   Rosenbrock, Johannes ^a   Halbsguth, Teresa ^a   Reiners, Katrin S ^a   Schober, Thomas ^a   Renno, Jorg H ^b   Von Wolff, Michael ^d   Van Der Ven, Katrin ^c   Kuehr, Marietta ^a   Fuchs, Michael ^a   Diehl, Volker ^a   Engert, Andreas ^a   Borchmann, Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Universitats Frauenklinik   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; TESTOSTERONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVOR; DISEASE SEVERITY; FEMALE; FERTILITY; FOLLOW UP; GERMANY; GONAD FUNCTION; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FERTILITY; FERTILITY PRESERVATION; FOLLICLE STIMULATING HORMONE; GERMANY; GONADOTROPIN-RELEASING HORMONE; HODGKIN DISEASE; HUMANS; INHIBINS; MALE; MENSTRUAL CYCLE; MIDDLE AGED; OLIGOSPERMIA; OVARY; PREDNISONE; PREGNANCY; PROCARBAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVORS; TESTIS; TESTOSTERONE; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 84872469193     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.3721     Document Type: Article

References (39)

1. Borchmann P, Topp MS, Behringer K, et al: Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: Results of the second interim analysis of the GHSG HD13 trial. Onkologie 33:124-125, 2010 (suppl 6)
2. von Tresckow B, Plu? tschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012
3. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012
4. Zebrack BJ, Mills J, Weitzman TS: Health and supportive care needs of young adult cancer patients and survivors. J Cancer Surviv 1:137-145, 2007
5. Gorman JR, Bailey S, Pierce JP, et al: How do you feel about fertility and parenthood? The voices of young female cancer survivors. J Cancer Surviv 6:200-209, 2012
6. Turner S, Maher EJ, Young T, et al: What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br J Cancer 73:222-227, 1996 (Pubitemid 26028338)
7. Biasoli I, Franchi-Rezgui P, Sibon D, et al: Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy. Ann Oncol 19:1915-1920, 2008
8. Letourneau JM, Ebbel EE, Katz PP, et al: Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 118:1710-1717, 2012
9. Quinn GP, Vadaparampil ST, Gwede CK, et al: Discussion of fertility preservation with newly diagnosed patients: Oncologists' views. J Cancer Surviv 1:146-155, 2007
10. Kiserud CE, Fossa A, Bjøro T, et al: Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 100:455-463, 2009
11. Sieniawski M, Reineke T, Josting A, et al: Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 19: 1795-1801, 2008
12. Behringer K, Breuer K, Reineke T, et al: Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23:7555-7564, 2005 (Pubitemid 46291819)
13. Kreuser E, Felsenberg D, Behles C, et al: Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 3:105-110, 1992 (suppl 4)
14. De Bruin ML, Huisbrink J, Hauptmann M, et al: Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 111:101-108, 2008
15. van Disseldorp J, Faddy MJ, Themmen AP, et al: Relationship of serum antimu? llerian hormone concentration to age at menopause. J Clin Endocrinol Metab 93:2129-2134, 2008 (Pubitemid 351831526)
16. Andersson AM, Petersen JH, Jørgensen N, et al: Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: Significance of adequate reference values from proven fertile men. J Clin Endocrinol Metab 89: 2873-2879, 2004 (Pubitemid 38766379)
17. Jensen TK, Andersson AM, Hjollund NH, et al: Inhibin B as a serum marker of spermatogenesis: Correlation to differences in sperm concentration and follicle-stimulating hormone levels - A study of 349 Danish men. J Clin Endocrinol Metab 82:4059-4063, 1997 (Pubitemid 27525512)
18. Heinemann K, Ruebig A, Potthoff P, et al: The Menopause Rating Scale (MRS) scale: A methodological review. Health Qual Life Outcomes 2:45, 2004
19. Potthoff P, Heinemann LA, Schneider HP, et al: [The Menopause Rating Scale (MRS II): Methodological standardization in the German population]. Zentralbl Gynakol 122:280-286, 2000
20. Moore C, Huebler D, Zimmermann T, et al: The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 46:80-87, 2004 (Pubitemid 38748514)
21. Heinemann LA, Moore C, Dinger JC, et al: Sensitivity as outcome measure of androgen replacement: The AMS scale. Health Qual Life Outcomes 4:23, 2006
22. Behringer K, Thielen I, Mueller H, et al: Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 23:1818-1825, 2012
23. La Marca A, Sighinolfi G, Radi D, et al: Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16:113-130, 2010
24. Lutchman Singh K, Davies M, Chatterjee R: Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 11:69-89, 2005 (Pubitemid 40201977)
25. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, et al: Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 92:3869-3874, 2007 (Pubitemid 47607635)
26. Tsepelidis S, Devreker F, Demeestere I, et al: Stable serum levels of anti-Mu? llerian hormone during the menstrual cycle: A prospective study in normo-ovulatory women. Hum Reprod 22:1837-1840, 2007 (Pubitemid 47062749)
27. Decanter C, Morschhauser F, Pigny P, et al: Anti-Mu? llerian hormone follow-up in young women treated by chemotherapy for lymphoma: Preliminary results. Reprod Biomed Online 20: 280-285, 2010
28. Anderson RA, Cameron DA: Pretreatment serum anti-mu? llerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 96: 1336-1343, 2011
29. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al: Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mu? llerian hormone. Hum Reprod 24:982-990, 2009
30. Gracia CR, Sammel MD, Freeman E, et al: Impact of cancer therapies on ovarian reserve. Fertil Steril 97:134-140.e1, 2012
31. Gubbels CS, Kuppens SM, Bakker JA, et al: Pregnancy in classic galactosemia despite undetectable anti-Mullerian hormone. Fertil Steril 91: 1293.e13-e16, 2009
32. Fraisse T, Ibecheole V, Streuli I, et al: Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil Steril 89: 723.e9-e11, 2008
33. van der Kaaij MA, Heutte N, Meijnders P, et al: Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol 30:291-299, 2012
34. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985
35. Bonadonna G: Modern treatment of malignant lymphomas: A multidisciplinary approach? The Kaplan Memorial Lecture. Ann Oncol 5:5-16, 1994 (suppl 2) (Pubitemid 24061313)
36. Kulkarni SS, Sastry PS, Saikia TK, et al: Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 20:354-357, 1997 (Pubitemid 27329566)
37. Holoch P, Wald M: Current options for preservation of fertility in the male. Fertil Steril 96:286-290, 2011
38. Waxman J, Terry Y, Wrigley P, et al: Gonadal function in Hodgkin's disease: Long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) 285:1612-1613, 1982 (Pubitemid 13237589)
39. Charak BS, Gupta R, Mandrekar P, et al: Testicular dysfunction after cyclophosphamidevincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease: A long-term follow-up study. Cancer 65:1903-1906, 1990 (Pubitemid 20147625)